The Short Version
Current New Zealand evidence supports the claim. PHARMAC’s schedule and decision records show that only sumatriptan and rizatriptan are publicly funded, while the other five triptan medicines used globally are not subsidised in New Zealand. Older sources about availability or approval do not rebut this, because they address access rather than public funding.